Contact person
Jennifer Rosendahl
Projektledare
Contact JenniferThe method is used to detect Mycoplasma contamination in biological samples, e.g., tissues, cells, gene therapies, cell therapy products, or tissue engineering products
Mycoplasma contamination is a widespread and recurring problem in in-vitro platforms in medical research and the pharmaceutical industry. Mycoplasma can grow in culture media without showing typical signs of bacterial contamination such as turbidity and does not affect cultured cells with altered metabolism, slower proliferation, and chromosomal abnormalities. This makes Mycoplasma testing and thus the maintenance of contamination-free in vitro systems fundamental to medical research and to the manufacture of goods in the pharmaceutical industry.
Mycoplasma is specifically detected by amplifying a highly conserved rRNA operon, or more specifically, a 16S rRNA coding region in the mycoplasma genome. Quantitative PCR (qPCR) is used to amplify this region. The method is validated according to European Pharmacopoeia 2.6.7 with different types of sample material.
Report with titer value